Pfizer's stock rating was lowered from Buy to Hold due to increasing analyst skepticism about its growth prospects and declining revenue and earnings expected through 2029. Despite management's optimistic projections and new pipeline drugs, including anti-obesity treatments from Metsera, concerns remain over patent expirations that could hurt future profits. Cost-cutting and pipeline updates are seen as insufficient to fully offset these challenges. Additionally, Pfizer's dividend sustainability is questioned as payouts nearly match free cash flow, raising the possibility of future dividend cuts. The stock's intrinsic value is estimated at $28.39, reflecting cautious investor sentiment.
Pfizer shares trade at USD 30.39 on Pluang as of Oct 30, 2026 22:21 WIB, just below their 52-week high of USD 30.42. Despite the article's cautious tone on growth and dividends, the stock gained 1.47% in the last day on Pluang, with a notable dividend yield of 5.74%. Investor activity shows a majority selling interest at 63%, reflecting some hesitation amid the company's earnings outlook.
Regeneron Pharmaceuticals' stock surged 12% after reporting a 36% revenue increase to $5.1 billion in Q3 2026, beating analyst expectations. The boost was largely due to its partnership with Sanofi, with Dupixent sales rising 35%, and record sales of...
A recent screen of the S&P 500 identified 11 stocks with high dividend yields that are well supported by their free cash flow, including notable companies such as Ford, Pfizer, and Verizon. These dividend stocks have been performing strongly, reflect...
Pfizer will report its Q3 2026 earnings on Nov 3, with investors watching if growth in obesity treatments and other new products can offset declines in COVID-related sales. The company has seen a 25% stock rise this year, driven by strong performance...
Moderna's stock fell 7% after its personalized melanoma vaccine, despite meeting its primary goal in a late-stage trial, showed less impact on distant cancer spread than earlier studies suggested. This has led investors to reassess the commercial pot...
